A new study of age-related macular degeneration, the disease that affects more than nine million Americans, will pave the way for the biopharmaceutical industry to develop better treatments and cures.
A new study of age-related macular degeneration, the disease that affects more than nine million Americans, will pave the way for the biopharmaceutical industry to develop better treatments and cures.